This pattern is comparable to the SMARCA4-normal group, where 146 patients (61.6%) were initially diagnosed with metastatic disease, 34 patients (14.3%) developed metastases due to progression after preoperative therapy, and 57 patients (24.1%) experienced recurrent disease at metastatic site following radical surgery. The gene discussed is SMARCA4; the disease is metastatic neoplasm.